Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2014-12-22 20:07:34
Reporting Period:
Filing Date:
Accepted Time:
2014-12-22 20:07:34
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
858803 Avanir Pharmaceuticals Inc. AVNR Pharmaceutical Preparations (2834) 330314804
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534986 Md Joao Siffert 30 Enterprise
Suite 400
Aliso Viejo CA 92656
Svp, R&d No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-18 32,291 $2.59 348,901 No 4 M Direct
Common Stock Disposition 2014-12-18 19,204 $16.99 329,697 No 4 F Direct
Common Stock Disposition 2014-12-18 15,505 $16.93 314,192 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-12-18 32,291 $0.00 32,291 $2.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-12-17 No 4 M Direct
  1. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
  2. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A majority of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs.
  3. Represents the weighted-average price at which shares were sold within a range between $16.93 and $16.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  4. The option was granted on 12/17/2012 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.